AVX101
/ AlphaVax
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 16, 2024
Safety and efficacy of intravenous OAV101 (AVXS-101) in pediatric patients with spinal muscular atrophy (SMA)
(clinicaltrialsregister.eu)
- P4 | N=16 | Sponsor: NOVARTIS BIOCIÊNCIAS S.A
New P4 trial • Genetic Disorders • Movement Disorders • Muscular Atrophy • Pediatrics • Rare Diseases • SMN1
August 31, 2023
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)
(clinicaltrials.gov)
- P4 | N=16 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed
Trial completion • Genetic Disorders • Movement Disorders • Muscular Atrophy • Pediatrics • Rare Diseases
1 to 2
Of
2
Go to page
1